secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2023-02-24T23:59:59+00:00
Accession:  0001104659-23-025392
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics prices $5.5M public offering of 1.05M shares at $5.25/share
------------------------------------------------------------------------------

- Gross proceeds ~$5.5M from 1,050,000 shares at $5.25/share; net proceeds ~$4.8M after discounts and expenses.
- Underwriters granted 30-day option to purchase up to 157,500 additional shares.
- Proceeds to fund clinical asset ATRN-119, pre-clinical ATRN-W1051, and general corporate purposes.
- Offering expected to close Feb 27, 2023; Maxim Group LLC sole book-runner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465923025392/0001104659-23-025392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465923025392/tm237532d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-025392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer